The potential role of the NLRP3 inflammasome as a link between mitochondrial complex I dysfunction and inflammation in bipolar disorder

Neural Plasticity

Volumn 2015, Issue , 2015, Pages

  Kim, Helena Kyunghee ^a   Chen, Wenjun ^a   Andreazza, Ana Cristina ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA CONVERTING ENZYME; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); AUTACOID; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN;

ARTICLE; BIPOLAR DISORDER; BRAIN MITOCHONDRION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; INFLAMMATION; MEDIATOR RELEASE; MENTAL PATIENT; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN ASSEMBLY; PROTEIN FUNCTION; ANIMAL; BRAIN; COMPLICATION; IMMUNOLOGY; METABOLISM;

ANIMALS; BIPOLAR DISORDER; BRAIN; CARRIER PROTEINS; ELECTRON TRANSPORT COMPLEX I; HUMANS; INFLAMMASOMES; INFLAMMATION; INFLAMMATION MEDIATORS; MITOCHONDRIAL DISEASES; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84930660923     PISSN: 20905904     EISSN: 16875443     Source Type: Journal    
DOI: 10.1155/2015/408136     Document Type: Article

References (101)

1. K. N. Fountoulakis, X. Gonda, M. Siamouli, and Z. Rihmer, "Psychotherapeutic intervention and suicide risk reduction in bipolar disorder: a review of the evidence", Journal of Affective Disorders, vol. 113, no. 1-2, pp. 21-29, 2009.
2. H. B. Clay, S. Sillivan, and C. Konradi, "Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia", International Journal of Developmental Neuroscience, vol. 29, no. 3, pp. 311-324, 2011.
3. M. Berk, F. Kapczinski, A. C. Andreazza et al., "Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors", Neuroscience & Biobehavioral Reviews, vol. 35, no. 3, pp. 804-817, 2011.
4. T. Kato and N. Kato, "Mitochondrial dysfunction in bipolar disorder", Bipolar Disorders, vol. 2, no. 3, pp. 180-190, 2000.
5. C. Konradi, S. E. Sillivan, and H. B. Clay, "Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis", Neurobiology of Disease, vol. 45, no. 1, pp. 37-47, 2012.
6. G. Scola, H. K. Kim, L. T. Young, and A. C. Andreazza, "A fresh look at complex i in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder", Biological Psychiatry, vol. 73, no. 2, pp. e4-e5, 2013.
7. A. C. Andreazza, L. Shoo, J. F. Wang, and L. Trevor Young, "Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder", Archives of General Psychiatry, vol. 67, no. 4, pp. 360-368, 2010.
8. M. J. López-Armada, R. R. Riveiro-Naveira, C. Vaamonde-García, and M. N. Valcárcel-Ares, "Mitochondrial dysfunction and the inflammatory response", Mitochondrion, vol. 13, no. 2, pp. 106-118, 2013.
9. R. Zhou, A. S. Yazdi, P. Menu, and J. Tschopp, "A role for mitochondria in NLRP3 inflammasome activation", Nature, vol. 469, pp. 221-225, 2011.
10. K. Nakahira, J. A. Haspel, V. A. K. Rathinam et al., "Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome", Nature Immunology, vol. 12, no. 3, pp. 222-230, 2011.
11. Z. Zhong, Y. Zhai, S. Liang et al., "TRPM2 links oxidative stress to NLRP3 inflammasome activation", Nature Communications, vol. 4, article 1611, 2013.
12. B. Halliwell, "Reactive oxygen species and the central nervous system", Journal of Neurochemistry, vol. 59, no. 5, pp. 1609-1623, 1992.
13. D. R. Green and G. Kroemer, "The pathophysiology of mitochondrial cell death", Science, vol. 305, no. 5684, pp. 626-629, 2004.
14. G. Lenaz, "The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology", IUBMB Life, vol. 52, no. 3-5, pp. 159-164, 2002.
15. R. J. R. J. Janssen, L. G. Nijtmans, L. P. Van Den Heuvel, and J. A. M. Smeitink, "Mitochondrial complex I: structure, function and pathology", Journal of Inherited Metabolic Disease, vol. 29, no. 4, pp. 499-515, 2006.
16. M. P. Vawter, H. Tomita, F. Meng et al., "Mitochondrialrelated gene expression changes are sensitive to agonal-pH state: implications for brain disorders", Molecular Psychiatry, vol. 11, no. 7, pp. 663-679, 2006.
17. S. Prabakaran, J. E. Swatton, M. M. Ryan et al., "Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress", Molecular Psychiatry, vol. 9, no. 7, pp. 684-697, 2004.
18. A. C. Andreazza, J. F. Wang, F. Salmasi, L. Shao, and L. T. Young, "Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder", Journal of Neurochemistry, vol. 127, no. 4, pp. 552-561, 2013.
19. A. C. Andreazza, M. Kauer-Sant'Anna, B. N. Frey et al., "Oxidative stress markers in bipolar disorder: a meta-analysis", Journal of Affective Disorders, vol. 111, no. 2-3, pp. 135-144, 2008.
20. D. P. Jones, "Redox sensing: orthogonal control in cell cycle and apoptosis signalling", Journal of Internal Medicine, vol. 268, no. 5, pp. 432-448, 2010.
21. M. Maes, E. Bosmans, J. Calabrese, R. Smith, and H. Y. Meltzer, "Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers", Journal of Psychiatric Research, vol. 29, no. 2, pp. 141-152, 1995.
22. A. M. Kilbourne, J. R. Cornelius, X. Han et al., "Burden of general medical conditions among individuals with bipolar disorder", Bipolar Disorders, vol. 6, no. 5, pp. 368-373, 2004.
23. K. Munkholm, J. V. Braüner, L. V. Kessing, and M. Vinberg, "Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis", Journal of Psychiatric Research, vol. 47, no. 9, pp. 1119-1133, 2013.
24. B. I. Goldstein, A. Fagiolini, P. Houck, and D. J. Kupfer, "Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States", Bipolar Disorders, vol. 11, no. 6, pp. 657-662, 2009.
25. S.-Y. M. Tsai, Y.-Y. Yang, C.-J. Kuo, C.-C. Chen, and S.-J. C. Leu, "Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania", Journal of Affective Disorders, vol. 64, no. 2-3, pp. 185-193, 2001.
26. H.-C. Tsai, M.-K. Lu, Y.-K. Yang et al., "Empirically derived subgroups of bipolar I patients with different comorbidity patterns of anxiety and substance use disorders in Han Chinese population", Journal of Affective Disorders, vol. 136, no. 1-2, pp. 81-89, 2012.
27. K.-P. Su, S.-J. C. Leu, Y.-Y. Yang, W. W. Shen, Y.-M. Chou, and S.-Y. M. Tsai, "Reduced production of interferon-gamma but not interleukin-10 in bipolar mania and subsequent remission", Journal of Affective Disorders, vol. 71, no. 1-3, pp. 205-209, 2002.
28. A. A. Wadee, R. H. Kuschke, L. A. Wood, M. Berk, L. Ichim, and M. Maes, "Serological observations in patients suffering from acute manic episodes", Human Psychopharmacology, vol. 17, no. 4, pp. 175-179, 2002.
29. Y.-K. Kim, H.-G. Jung, A.-M. Myint, H. Kim, and S.-H. Park, "Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder", Journal of Affective Disorders, vol. 104, no. 1-3, pp. 91-95, 2007.
30. M. N. Breunis, R. W. Kupka, W. A. Nolen et al., "High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder", Biological Psychiatry, vol. 53, no. 2, pp. 157-165, 2003.
31. F. Boufidou, C. Nikolaou, B. Alevizos, I. A. Liappas, and G. N. Christodoulou, "Cytokine production in bipolar affective disorder patients under lithium treatment", Journal of Affective Disorders, vol. 82, no. 2, pp. 309-313, 2004.
32. S. M. O'Brien, P. Scully, L. V. Scott, and T. G. Dinan, "Cytokine profiles in bipolar affective disorder: focus on acutely ill patients", Journal of Affective Disorders, vol. 90, no. 2-3, pp. 263-267, 2006.
33. F. Dickerson, C. Stallings, A. Origoni et al., "Acombinedmarker of inflammation in individuals with mania", PLoS ONE, vol. 8, no. 9, Article IDe73520, 2013.
34. T. L. Huang and F. C. Lin, "High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania", Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 2, pp. 370-372, 2007.
35. M. Kauer-Sant'Anna, F. Kapczinski, A. C. Andreazza et al., "Brain-derived neurotrophic factor and inflammatory markers in patients with early-vs. late-stage bipolar disorder", The International Journal of Neuropsychopharmacology, vol. 12, no. 4, pp. 447-458, 2009.
36. F. Kapczinski, F. Dal-Pizzol, A. L. Teixeira et al., "Peripheral biomarkers and illness activity in bipolar disorder", Journal of Psychiatric Research, vol. 45, no. 2, pp. 156-161, 2011.
37. I. G. Barbosa, N. P. Rocha, A. S. D. Miranda et al., "Increased levels of adipokines in bipolar disorder", Journal of Psychiatric Research, vol. 46, no. 3, pp. 389-393, 2012.
38. I. G. Barbosa, N. P. Rocha, M. E. Bauer et al., "Chemokines in bipolar disorder: trait or state?" European Archives of Psychiatry and Clinical Neuroscience, vol. 263, no. 2, pp. 159-165, 2013.
39. I. G. Barbosa, I. B. Morato, A. S. De Miranda, M. E. Bauer, J. C. Soares, and A. L. Teixeira, "A preliminary report of increased plasma levels of IL-33 in bipolar disorder: further evidence of pro-inflammatory status", Journal of Affective Disorders, vol. 157, pp. 41-44, 2014.
40. A. Remlinger-Molenda, P. Wojciak, M. Michalak, J. Karczewski, and J. K. Rybakowski, "Selected cytokine profiles during remission in bipolar patients", Neuropsychobiology, vol. 66, no. 3, pp. 193-198, 2012.
41. T. Cetin, S. Guloksuz, E. A. Cetin et al., "Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms", BMC Psychiatry, vol. 12, article 158, 2012.
42. A. Ortiz-Domínguez, M. E. Hernández, C. Berlanga et al., "Immune variations in bipolar disorder: phasic differences", Bipolar Disorders, vol. 9, no. 6, pp. 596-602, 2007.
43. A. B. M. Cunha, B. N. Frey, A. C. Andreazza et al., "Serumbrainderived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes", Neuroscience Letters, vol. 398, no. 3, pp. 215-219, 2006.
44. S. Hope, I. Dieset, I. Agartz et al., "Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia", Journal of Psychiatric Research, vol. 45, no. 12, pp. 1608-1616, 2011.
45. S. Guloksuz, K. Altinbas, E. Aktas Cetin et al., "Evidence for an association between tumor necrosis factor-alpha levels and lithiumresponse", Journal of Affective Disorders, vol. 143, no. 1.3, pp. 148-152, 2012.
46. E. Brietzke, R. Stabellini, R. Grassi-Oliveira, and B. Lafer, "Cytokines in bipolar disorder: recent findings, deleterious effects but promise for future therapeutics", CNS Spectrums, vol. 16, no. 7, pp. 157-168, 2011.
47. R. C. Drexhage, E. M. Knijff, R. C. Padmos et al., "The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder", Expert Review of Neurotherapeutics, vol. 10, no. 1, pp. 59-76, 2010.
48. E. A. Carswell, L. J. Old, R. L. Kassel, S. Green, N. Fiore, and B. Williamson, "An endotoxin induced serum factor that cuases necrosis of tumors", Proceedings of the National Academy of Sciences of the United States of America, vol. 72, no. 9, pp. 3666-3670, 1975.
49. A. Koj, D. Magielska-Zero, J. Bereta, A. Kurdowska, H. Rokita, and J. Gauldie, "The cascade of inflammatory cytokines regulating synthesis of acute phase proteins", The Tokai Journal of Experimental and Clinical Medicine, vol. 13, no. 6, pp. 255-264, 1988.
50. B. Dean, A. S. Gibbons, N. Tawadros, L. Brooks, I. P. Everall, and E. Scarr, "Different changes in cortical tumor necrosis factor-α-related pathways in schizophrenia and mood disorders", Molecular Psychiatry, vol. 18, no. 7, pp. 767-773, 2013.
51. W. A. Banks, A. J. Kastin, and R. D. Broadwell, "Passage of cytokines across the blood-brain barrier", Neuro Immunomodulation, vol. 2, no. 4, pp. 241-248, 1995.
52. J. S. Rao, G. J. Harry, S. I. Rapoport, and H. W. Kim, "Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients", Molecular Psychiatry, vol. 15, no. 4, pp. 384-392, 2010.
53. J. Söderlund, S. K. Olsson, M. Samuelsson et al., "Elevation of cerebrospinal fluid interleukin-1β in bipolar disorder", Journal of Psychiatry & Neuroscience, vol. 36, no. 2, pp. 114-118, 2011.
54. J. C. Felger, L. Li, P. J. Marvar et al., "Tyrosinemetabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations", Brain, Behavior, and Immunity, vol. 31, pp. 153-160, 2013.
55. J. C. Felger and A. H. Miller, "Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise", Frontiers in Neuroendocrinology, vol. 33, no. 3, pp. 315-327, 2012.
56. S. T. Dheen, C. Kaur, and E.-A. Ling, "Microglial activation and its implications in the brain diseases", Current Medicinal Chemistry, vol. 14, no. 11, pp. 1189-1197, 2007.
57. M. Berk, L. Berk, S. Dodd et al., "Stage managing bipolar disorder", Bipolar Disorders, vol. 16, no. 5, pp. 471-477, 2014.
58. M. Berk, S. Dodd, M. Kauer-Sant'anna et al., "Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder", Acta Psychiatrica Scandinavica, no. 434, pp. 41-49, 2007.
59. M. T. Sorbara and S. E. Girardin, "Mitochondrial ROS fuel the inflammasome", Cell Research, vol. 21, no. 4, pp. 558-560, 2011.
60. T. Boller and G. Felix, "A renaissance of elicitors: perception of microbe-associated molecular patterns and danger signals by pattern-recognition receptors", Annual Review of Plant Biology, vol. 60, pp. 379-407, 2009.
61. C. Bryant and K. A. Fitzgerald, "Molecular mechanisms involved in inflammasome activation", Trends in Cell Biology, vol. 19, no. 9, pp. 455-464, 2009.
62. B. Beutler, Z. Jiang, P. Georgel et al., "Genetic analysis of host resistance: toll-like receptor signaling and immunity at large", Annual Review of Immunology, vol. 24, pp. 353-389, 2006.
63. L. Agostini, F. Martinon, K. Burns, M. F. McDermott, P. N. Hawkins, and J. Tschopp, "NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder", Immunity, vol. 20, no. 3, pp. 319-325, 2004.
64. J. Tschopp and K. Schroder, "NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?" Nature Reviews Immunology, vol. 10, no. 3, pp. 210-215, 2010.
65. K. Schroder, R. Zhou, and J. Tschopp, "The NLRP3 inflammasome: a sensor formetabolic danger?" Science, vol. 327, no. 5963, pp. 296-300, 2010.
66. B. Harwell, "Biochemistry of oxidative stress", Biochemical Society Transactions, vol. 35, no. 5, pp. 1147-1150, 2007.
67. D. Perregaux and C. A. Gabel, "Interleukin-1β maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity", The Journal of Biological Chemistry, vol. 269, no. 21, pp. 15195-15203, 1994.
68. C. Eder, "Mechanisms of interleukin-1β release", Immunobiology, vol. 214, no. 7, pp. 543-553, 2009.
69. N. B. Bryan, A. Dorfleutner, S. J. Kramer, C. Yun, Y. Rojanasakul, and C. Stehlik, "Differential splicing of the apoptosis-associated speck like protein containing a caspase recruitment domain (ASC) regulates inflammasomes", Journal of Inflammation, vol. 7, article 23, 2010.
70. A. Weber, P. Wasiliew, and M. Kracht, "Interleukin-1β (IL-1β) processing pathway", Science Signaling, vol. 3, no. 105, p. cm2, 2010.
71. M. Lamkanfi and V. M. Dixit, "Inflammasomes: guardians of cytosolic sanctity", Immunological Reviews, vol. 227, no. 1, pp. 95-105, 2009.
72. D. Liu, A. M. Rhebergen, and S. C. Eisenbarth, "Licensing adaptive immunity by NOD-like receptors", Frontiers in Immunology, vol. 4, article 486, Article ID Article 486, 2013.
73. N. Li, K. Ragheb, G. Lawler et al., "Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production", The Journal of Biological Chemistry, vol. 278, no. 10, pp. 8516-8525, 2003.
74. T. Lane, B. Flam, R. Lockey, and N. Kolliputi, "TXNIP shuttling: missing link between oxidative stress and inflammasome activation", Frontiers in Physiology, vol. 4, article 50, 2013.
75. H. Parikh, E. Carlsson, W. A. Chutkow et al., "TXNIP regulates peripheral glucose metabolism in humans", PLoSMedicine, vol. 4, no. 5, article e158, 2007.
76. A. H. Minn, C. Hafele, and A. Shalev, "Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces β-cell apoptosis", Endocrinology, vol. 146, no. 5, pp. 2397-2405, 2005.
77. J. Chen, G. Saxena, I. N. Mungrue, A. J. Lusis, and A. Shalev, "Thioredoxin-interacting protein: a critical link between glucose toxicity and β-cell apoptosis", Diabetes, vol. 57, no. 4, pp. 938-944, 2008.
78. C. V. Calkin, D. M. Gardner, T. Ransom, and M. Alda, "The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders", Annals of Medicine, vol. 45, no. 2, pp. 171-181, 2013.
79. K. Shimada, T. R. Crother, J. Karlin et al., "Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis", Immunity, vol. 36, no. 3, pp. 401-414, 2012.
80. J. J. Lemasters, T. P. Theruvath, Z. Zhong, and A.-L. Nieminen, "Mitochondrial calcium and the permeability transition in cell death", Biochimica et Biophysica Acta: Bioenergetics, vol. 1787, no. 11, pp. 1395-1401, 2009.
81. J. Trnka, F. H. Blaikie, A. Logan, R. A. Smith, and M. P. Murphy, "Antioxidant properties of Mito TEMPOL and its hydroxylamine", Free Radical Research, vol. 43, no. 1, pp. 4-12, 2009.
82. J. Jiang, D. A. Stoyanovsky, N. A. Belikova et al., "A mitochondriatargeted triphenylphosphonium-conjugated nitroxide functions as a radioprotector/mitigator", Radiation Research, vol. 172, no. 6, pp. 706-717, 2009.
83. A. M. Myint, H. W. M. Steinbusch, L. Goeghegan, D. Luchtman, Y. K. Kim, and B. E. Leonard, "Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression", Neuro Immuno Modulation, vol. 14, no. 2, pp. 65-71, 2007.
84. P. Casolini, A. Catalani, A. R. Zuena, and L. Angelucci, "Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat", Journal of Neuroscience Research, vol. 68, no. 3, pp. 337-343, 2002.
85. F. G. Nery, E. S. Monkul, J. P. Hatch et al., "Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebocontrolled study", Human Psychopharmacology, vol. 23, no. 2, pp. 87-94, 2008.
86. J. Savitz, S. Preskorn, T. K. Teague, D. Drevets, W. Yates, and W. Drevets, "Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, doubleblind, placebo-controlled, 2×2 clinical trial", BMJ Open, vol. 2, no. 1, Article ID000643, 2012.
87. P. Stolk, P. C. Souverein, I. Wilting et al., "Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder", Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 82, no. 1, pp. 9-14, 2010.
88. G. R. Weerasinghe, S. I. Rapoport, and F. Bosetti, "The effect of chronic lithium on arachidonic acid release and metabolism in rat brain does not involve secretory phospholipase A2 or lipoxygenase/cytochrome P450 pathways", Brain Research Bulletin, vol. 63, no. 6, pp. 485-489, 2004.
89. E. Ramadan, M. Basselin, J. S. Rao et al., "Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder", International Journal of Neuropsychopharmacology, vol. 15, no. 7, pp. 931-943, 2012.
90. D. A. Lowes, A. M. Almawash, N. R. Webster, V. L. Reid, and H. F. Galley, "Melatonin and structurally similar compounds have differing effects on inflammation and mitochondrial function in endothelial cells under conditions mimicking sepsis", British Journal of Anaesthesia, vol. 107, no. 2, pp. 193-201, 2011.
91. V. Srinivasan, D. W. Spence, S. R. Pandi-Perumal, G. M. Brown, and D. P. Cardinali, "Melatonin in mitochondrial dysfunction and related disorders", International Journal of Alzheimer's Disease, vol. 2011, Article ID 326320, 16 pages, 2011.
92. Y. K. Kim, I. B. Suh, H. Kim et al., "The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: Effects of psychotropic drugs", Molecular Psychiatry, vol. 7, no. 10, pp. 1107-1114, 2002.
93. Y.-K. Kim, A.-M. Myint, B.-H. Lee et al., "T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients", Psychiatry Research, vol. 129, no. 3, pp. 267-272, 2004.
94. H.-C. Liu, Y.-Y. Yang, Y.-M. Chou, K.-P. Chen, W. W. Shen, and S.-J. Leu, "Immunologic variables in acute mania of bipolar disorder", Journal of Neuroimmunology, vol. 150, no. 1-2, pp. 116-122, 2004.
95. E. M. Knijff, M. N. Breunis, M. C. Van Geest et al., "A relative resistance of T cells to dexamethasone in bipolar disorder", Bipolar Disorders, vol. 8, no. 6, pp. 740-750, 2006.
96. F. Dickerson, C. Stallings, A. Origoni, J. Boronow, and R. Yolken, "Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder", Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 4, pp. 952-955, 2007.
97. E. M. Knijff, M. N. Breunis, R. W. Kupka et al., "An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment", Bipolar Disorders, vol. 9, no. 7, pp. 743-753, 2007.
98. A. B. Cunha, A. C. Andreazza, F. A. Gomes et al., "Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder", European Archives of Psychiatry and Clinical Neuroscience, vol. 258, no. 5, pp. 300-304, 2008.
99. S. Guloksuz, E. A. Cetin, T. Cetin, G. Deniz, E. T. Oral, and D. J. Nutt, "Cytokine levels in euthymic bipolar patients", Journal of Affective Disorders, vol. 126, no. 3, pp. 458-462, 2010.
100. E. Brietzke and A. L. Teixeira, "Similar immune profile in bipolar disorder and schizophrenia: Selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor", Bipolar Disorders, vol. 12, no. 4, pp. 453-454, 2010.
101. I. G. Barbosa, R. B. Huguet, V. A. Mendonça et al., "Increased plasma levels of soluble TNF receptor i in patients with bipolar disorder", European Archives of Psychiatry and Clinical Neuroscience, vol. 261, no. 2, pp. 139-143, 2011.